Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation

X
Trial Profile

A Double-Blind, Placebo-Controlled, Dose-Finding Trial to Evaluate the Efficacy and Safety of Prucalopride (R093877) in Subjects With Chronic Idiopathic Constipation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 Dec 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Prucalopride (Primary)
  • Indications Constipation
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Shire-Movetis NV
  • Most Recent Events

    • 28 Oct 2020 Results assessing effect of retreatment and treatment cessation in clinical studies of prucalopride in patients with chronic idiopathic constipation, presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2020
    • 10 May 2011 Pooled results of three phase II trials [see trial profiles 700030527, 700032139 and 700199472] presented at the Digestive Disease Week 2011.
    • 22 Oct 2008 Results presented at UEGW (abstract P0894).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top